Biological effects of short-term, high-concentration exposure to methyl isocyanate. VI. In vitro and in vivo complement activation studies. by Kolb, W P et al.
EnvironmentalHealthPerspectives
Vol. 72, pp. 189-195, 1987
Biological Effects of Short-Term, High-
Concentration Exposure to Methyl
Isocyanate. VI. In Vitro and In Vivo
Complement Activation Studies
by William P. Kolb,* Jay R. Savary,* Catherine M. Troup,t
Darol E. Dodd,t and John D. Tamerius*
The ability of MIC to induce complement activation in vitro and in vivo was investigated. For the in
vitro studies, both human and guinea pig serum or EDTA-plasma samples were exposed to 1167 to 1260
ppm MIC vapor for 15 min at room temperature. The human serum samples exposed to MIC showed
significant reductions in Factor B, C2, C4, C3, C5, and total hemolytic complement CH50 activity levels.
C6 functional activity was unaffected. The C3, C5, andCH50 functional activities in guinea pig serum (the
only functional tests conducted on these samples) were more sensitive to MIC-mediated reduction than
the corresponding activity reductions observed inthe human serum samples. The human and single guinea
pig EDTA-plasma samples exposed to MIC vapor showed no evidence of C3 consumption but did show
significant reductions in CH50 levels. Thus, MIC vapor was able to activate, and thereby reduce serum
complement C3 activity in vitro by a complement-dependent process. However, the data suggest at least
one complement component otherthan C3 was inactivated in EDTA-plasma by acomplement-independent
mechanism.
For the in vivo studies, five pairs ofguinea pigs were exposed to 644 to 702 ppm MIC vapor until one of
the pair died (11-15 min). MIC exposure was then discontinued, the surviving guinea pig was sacrificed,
and EDTA-plasma was obtained from both animals and analyzed for complement consumption. Clear
evidence was obtained to indicate that complement activation had occurred in these animals exposed to
MIC for 11 to 15 min. In addition, the complement activation profile observed in these guinea pigs was
qualitatively similar to that seen in the guinea pig serum samples exposed to MIC vapor in vitro. The total
protein concentration present in plasma samples obtained from guinea pigs that had died from MIC
exposure was elevated significantly (p < 0.05) above the total protein concentration present in plasma
samples obtained from these same animals before MIC exposure or from paired animals which had not
died (sacrificed) from MIC exposure. The possible contribution of complement activation to the fatal
reaction(s) observed in these MIC-treated animals is discussed.
Introduction
Complement (C) is a cascade system of circulating
plasma proteins consisting of 20 different components
that collectively represent approximately 10 to 15% of
the globulin, i.e., nonalbumin fraction ofnormal human
serum (1-4). In general, complement components are
activated sequentially upontheconversion ofaninactive
zymogen to an active proteolytic enzyme capable of
cleaving, and thereby activating the next component in
the reaction sequence (1-4). Polypeptide fragements of
complement proteins produced as a result of cleavage
by complement enzymes, as well as the subcomponents
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of the C1 complex, are designated by a small letter,
e.g., the fifth component of complement (C5) is frag-
mented to C5a and C5b polypeptides as a result ofcom-
plement activation (5).
Complement activation can be triggered via two dis-
tinct and separate pathways termed''the classical and
alternative activation pathways (1-4). The complement
proteins unique to the classical pathway are Cl, a cal-
cium-dependent complex of subcomponents Clq, Clr,
and Cls (present in the Cl complex in molar ratios of
1:2:2respectively), C4, and C2. Initiation oftheclassical
pathway of complement activation is triggered upon
binding of Clq either to IgG or IgM-immunoglobulin
containing antigen-antibody complexes (immune com-
plexes) orto avariety ofbiologically relevantactivating
substances, as detailed in a recent review by Cooper
(6).KOLB ETAL.
Complement proteins which are unique to the alter-
native pathway of complement activation are Factors
B, D, and P (properdin) (3). However, functional alter-
native pathway activation also requires the presence of
the complement regulator proteins Factor H (B1H) and
Factor I (C3b inactivator) (7). Alternative pathway ac-
tivation is triggered by IgA containing immune com-
plexes and a variety of naturally occurring microbial
and eukaryotic cellular products (3). Initiation ofeither
complement activation pathway leads to the activation
of the C3 through C9 components of complement re-
sulting in assembly ofthe C5b-9 complex on the target
surface (4).
Complement activation can result in the expression
of at least three distinct, physiologically relevant bio-
logical activities: (1) opsonization and enhanced phag-
ocytosis of complement-coated target cells or particles
by phagocytic white cells [target particle-bound C3 and
C4activationfragmentsmediatethisactivitybybinding
to complement receptors present on the outer mem-
brane surfaces of phagocytic white cells (8)]; (2) irre-
versible structural and functional damage to target
membranes resulting in cytolysis mediated by the C5b-
9 membrane attack complex (4); and (3) activation of
specialized physiological as well as cellular functions.
The C4a, C3a, and C5a anaphylatoxin activation pep-
tides are the complement mediators ofthese physiolog-
ical and cellular functions which can initiate or contrib-
ute to acute inflammatory responses. The complement
anaphylatoxins havetheabilitytoinduce smoothmuscle
contraction, increase vascularpermeability, andrelease
histamine from mast cells (9). In addition to its ana-
phylatoxinactivities, C5ais also averypotentmediator
oflysosomal enzyme release and directed chemotaxis of
polymorphonuclear neutrophils and monocytes (9,10).
The complement system, i.e., complement anaphy-
latoxinsinparticular, is veryimportantinthemediation
ofacute inflammatory injury in the lung. For example,
monkeysimmunized againstpigeon serum(11)orguinea
pigs immunized against ovalbumin (12) develop acute
hemorrhagic, exudative alveolitis within 2 hr following
aerosolantigenchallenge. Thepulmonaryinflammatory
damage observed in these models oflung injury is sup-
pressed if the animals are complement depleted with
cobra venomfactorprior to antigen challenge (12). Fur-
thermore, several lines of evidence have implicated a
major role for complement activation in the mediation
and/or perpetuation of acute lung inflammatory injury
observed in the adult respiratory distress syndrome
(ARDS). Thus, a neutrophil-stimulating factor, appar-
ently C5-derived, has been reported to be present in
the plasma ofARDS patients (13). The lung injury as-
sociated with sepsis in animal models ofARDS, either
inguinea pigs ormice, was found to be complement and
neutrophil dependent (14). C5a, C5a des arg, and C5
activated by noncomplement proteases (C5') produce
acuteinflammatory lunginjury inexperimental animals
subsequent to intratracheal instillation, which mor-
phologically resembles the lung injury observed in
ARDS (15,16). In addition, a recent study by Stevens
et al. (17) that used a primate model ofARDS induced
by acute E. coli sepsis demonstrated that IV perfusion
of an antibody reactive with human C5a anaphylatoxin
effectively protected these animals against severe lung
injury.
Since MIC inhalation by experimental animals pro-
duces major structural and functional pulmonary. ab-
normalities (18), the effects ofMIC on the complement
system were investigated both invitro by usinghuman
orguineapigserumand EDTA-plasmasamples, aswell
as in vivo by using a guinea pig inhalation model (19).
Materials and Methods
In Vitro MIC Exposure Studies
Blood samples were collected from human volunteers
by venipuncture into vacutainers (Becton-Dickinson,
Co., Rutherford, NJ) forthe preparation ofserum (red-
toptubes) orEDTA-plasma(lavender-toptubes). Three
tofivemillilitersofEDTA-wholebloodwerecentrifuged
immediately after collection at 1200g for 20 min at 4°C
in a refrigerated centrifuge. Seven to ten milliliters of
whole blood collected in red-top vacutainers were clot-
ted at 370C for 20 min, the clot was reamed, and the
vacutainer tubes were incubated at 370C for an addi-
tional 30 min. The EDTA-plasma or serum samples
were exposed to MIC or air alone immediately after
preparation. Afterexperimentalexposure, asdescribed
below, all samples were immediately frozen at -70°C in
100- to 200-,iL portions until analyzed. Portions ofthe
EDTA-plasmaorserumsamplesreceivingnotreatment
whatsoever (untreated controls) were frozen immedi-
ately after preparation at -70°C in 100- to 200-,uL por-
tions until analyzed.
Samples were exposed to statically generated MIC
vapor in an inhalation chamber (19) for 15 min at room
temperature. Individual EDTA plasma or serum sam-
ples, 2 mL each, were placed into 30-mL beakers on a
stir plate (Sybran Nuova 7 Stir Plate) with a magnetic
stir bar operating at approximately 50 rpm. Sham-ex-
posed control samples were exposed to air only in the
inhalation chamber by the same procedure for 15 min
atroomtemperature. Afterexposure, thesampleswere
removed from the exposure chamber and placed on ice
in the chamber glove box for approximately 30 min to
ensure that all the MIC vapor had dissipated from the
experimental specimens. All samples were then frozen
at -70°C in 100- to 200-RL portions until analyzed.
Inhalation Studies
Specific pathogen-free, female Sprague-Dawley
guinea pigs (Hazelton-Research Animals, Denver, PA)
were exposed to a target MIC vapor concentration of
650 ppm as described by Dodd et al. (19). Five groups
of two animals were exposed to a target concentration
of 650 ppm MIC until one of the animals died. At this
point, MIC exposure wasdiscontinued andEDTA-blood
was collected as quickly as possible from the abdominal
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aorta of the guinea pig which died. EDTA-plasma was
prepared as described above. Concomitantly, the sur-
viving guinea pig was sacrificed using methoxyfluorane
anestheticandEDTA-plasmawascollectedasdescribed
above. All EDTA-plasma samples were frozen imme-
diately in single-use aliquots (100 piL) and stored at
-70°C until analyzed.
Complement Reagents and Test
Procedures
CH50 (20), C3 (21), C5 (22), and C6 (23) quantitative
hemolytic activity assays were conducted as described.
C4 functional activity was quantitated by incubating 25
,uL of the sample dilution to be tested with 10 ,L C4-
deficient guinea pig serum and 3 x 107 EA (antibody
sensitized sheep erythrocytes) in a final volume of 50
,uL GVB+ + (5mMbarbital, 135mMNaCl, 0.1%gelatin,
0.5 mM MgC92, 0.15 mM CaC12, pH 7.4) for 30 min at
37°C. C2 and Factor B functional activity levels were
quantitated byusingimmunochemically depleted C2- or
Factor B-depleted human serum obtained from Cyto-
tech, Inc. (SanDiego, CA)followingtheirrecommended
procedure.
Concentrations of iC3b in the human serum and
plasma samples were quantitated by using monoclonal
antibody 013III-1 obtained from Cytotech, Inc. (San
Diego, CA). This monoclonal antibody is specific for a
neo-antigenic determinant which is expressed by the
iC3b catabolic fragment of C3 activation, but is not ex-
pressedbynative C3 andisnotexpressedbyC3b, C3d,g
or C3d fragments (24). The 013III-1 monoclonal anti-
body was employed in a quantitative enzyme immu-
noassay (EIA) in which the monoclonal antibody was
coated onto polystyrene microtiter plates, 100 pL/well,
at 5 ,ug monoclonal antibody/mL borate buffered saline
(25 mM sodiumborate, 100mMboricacid, 75mM NaCl,
pH8.3) for 16to24hrat4°C. Duplicate, 100 ,uLportions
of diluted specimen samples were incubated with
013III-1 coated wells for 30 min at room temperature
(22°C). The wells were washed three times with PBS
plus 0.05% Tween20 byfloodingand decanting, and 100
,L ofHRP-conjugated goat anti-human C3 were added
per well for 30 min at 22°C. The wells were washed
three times with PBS plus 0.05% Tween 20 by flooding
and decanting. A 100 FL volume of 0.034% 2-2'-azino-
di-(3-ethylbenzthiazoline sulfonicacid) diammonium salt
(ABTS) in 100 mM sodium citrate, pH 4.0, plus 0.0126%
hydrogen peroxide was added per well for 30 min at
22°C. The HRP enzymatic reaction was stopped by the
addition of 50 pL1 0.01% sodium azide. All wells were
read at 405 nm with an automated Titertek Multiskan
MC plate reader, and the iC3b concentration was de-
termined from a standard curve run with each set of
test samples.
Protein Determinations
Protein determinations were performed by the Folin
procedure of Lowry (25).
Statistics
A significant change (p < 0.05) in complement com-
ponent activity subsequent to in vitro or in vivo MIC
exposure was determined by a one-way analysis ofvar-
iance on the experimental data points before normali-
zation to sham-exposed control values. Where appro-
priate, results arereported asthemean + onestandard
deviation (SD).
Results and Discussion
Four different normal human serum and matched
EDTA-plasma samples were exposed to 1167 ppm MIC
vapor or air alone (sham-exposed control) for 15 min.
The results from this set of experiments are seen in
Table 1. The human serum samples exposed to MIC
vapor showed significant reductions in total hemolytic
complement CH50 levels, as well as significant reduc-
tions in the specificfunctionalactivities ofFactorB, C2,
C4, C3, and C5. In addition, all MIC-treated samples
exhibited significantly increased quantities of iC3b, a
breakdown fragment of C3 activation, as compared to
sham-exposed control samples. In fact, the serum CH50
and iC3b values correlated well with each other, i.e.,
the greater the reduction in CH50 activity, the greater
the amount ofiC3b produced. Serum C6 functional ac-
tivity levels were unaffected by MIC exposure.
From these results (Table 1) it appears that both
complement pathways had been activated in the human
serum samples since Factor B, C2, and C4 levels were
all reduced to approximately the same extent. Activa-
tion of both pathways was further supported by the
observation that no iC3b was formed in the human
EDTA-plasma samples upon exposure to MIC vapor.
Therefore, the C3 activation event in serum appeared
to be dependent upon the presence ofdivalent cations.
The effect of MIC exposure on the complement sys-
tem in guinea pig serum or EDTA-plasma was also in-
vestigated. As seen in Table 2, the CH50 and C5 func-
tionalactivities inguineapigserumweremore sensitive
to inactivation, following a 15 min in vitro exposure to
1260 ppm MIC vapor, than the corresponding activities
observed in the human serum samples (Table 1). How-
ever, the generalprofile ofcomplement component con-
sumption was qualitatively similar. Namely, of the
three complement functional activities tested in the
guinea pig serum samples, the C3 levels demonstrated
the smallest activity reduction while the CH50 and C5
levels demonstrated much greater activity reductions.
The complement CH50 activity measured in the
guinea pig EDTA-plasma sample (Table 2) appeared
more sensitive to MIC-mediated consumption than the
corresponding CH50 activity measured in the human
EDTA-plasma sample (Table 1) (note n= 1). These re-
sults further indicated that in both human and guinea
pigplasmaexposedtoMICvapor, thereductioninCH5;
activitywasmuchgreaterthanthereductioninC3func-
tionalactivity (inthe caseofthehumanplasmasamples,
an insignificant increase in iC3b levels subsequent to
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Table 1. Consumption of complement activity in normal human serum and EDTA-plasma
following 15 min in vitro exposure to 1167 ppm MIC vapor.
Consumption of complement activity
Seruma Plasmaa
Sample no. Treatment CH50 Factor B C2 C4 C3 iC3b C5 C6 CHrO iC3b
1 MIC 51.4a 24.6 65.2 75.0 81.8 980.0 22.2 104.1 100.0
2 MIC 65.9 40.6 54.5 46.7 73.1 360.0 16.2 86.3 100.0
3 MIC 42.3 31.2 70.7 50.0 76.2 4410.0 27.3 112.2 59.8 100.0
4 MIC 67.0 91.4 79.1 53.8 100.0 312.0 24.3 108.2 71.8
Average MIC 56.7* 47.0* 67.4* 56.4* 82.8* 1515.5t 22.5* 102.7 59.8 93.0
SD 11.9 30.4 10.3 12.8 12.0 1953.5 4.7 11.4 14.1
aAll numbers represent the percent of sham-exposed (0 ppm MIC) control values.
*Significantly different from the sham-exposed (0 ppm MIC) control values, p <0.05.
tSignificantly different from the sham-exposed (0 ppm MIC) control values, p <0.10.
Table 2. Consumption of complement activity in normal guinea pig serum and
EDTA-plasma following 15 min in vitro exposure to 1260 ppm MIC vapor.
Consumption of complement activity
Seruma Plasmaa
Sample no. Treatment CH50 C3 C5 CHrO C3 C5
1 MIC 0 30.9 15.6 -
2 MIC 0 22.0 0 -
3 MIC 0 11.5 0 -
4 MIC 0 78.5 36.2
Average MIC 0* 21.5* 5.2* 0 78.5 36.2
SD 9.7 9.0
aAll numbers represent the percent of sham-exposed control values.
*Significantly different from the sham-exposed (0 ppm MIC) control values, p <0.05.
MIC exposure was interpreted toindicate that C3 func-
tional activity was unaffected). This observation
strongly suggested that one or more of the classical
pathway proteins was inactivated directly by MIC in
the absence ofdivalent cations, i.e., in the presence of
10 mM EDTA. On the other hand, as indicated in both
Tables 1 and2, C3consumption did occurinbothhuman
and guinea pig serum by a complement-dependent pro-
cess. This conclusion is based upon the significant re-
duction in C3 activity observed in the human or guinea
pig serum samples as compared to the EDTA-plasma
samples after MIC vapor exposure.
Guinea pig serum and matched EDTA-plasma sam-
ples were also exposed to a target concentration of225
ppmMIC vaporusingthesameexperimentalprocedure
as described above. The results from this study (data
not shown) indicated that 225 ppm MIC vapor induced
a complement consumption proffle which was similar to
that observed in Table 2, however, the extent of com-
plement consumption was not as great. For example,
three guinea pig serum samples exposed to 225 ppm
MIC vaporinvitro demonstrated average CH50 and C5
values, when expressed as a percent of sham-treated
controls, of42% and 37%, respectively.
To investigate the in vivo effects of MIC inhalation,
paired guinea pigs were exposed to atarget MIC vapor
concentration of650 ppm until one ofthe pair died (11-
15 min). The MIC exposure was discontinued, the sec-
ond animal was sacrificed, and EDTA-plasma samples
were obtained from both animals as described in "Ma-
terials and Methods." The EDTA-plasma samples were
assayed forCH50, C3, and C5complementactivities and
the results are presented in Tables 3 and 4 as activity
units per mL as well as activity units per mg protein.
As seen in Tables 3 and 4, complement activation had
occurred during the short time period (approximately
11-15 min) these animals were exposed to MIC vapor.
In addition, the complement activationprofile observed
in these animals was qualitatively similar to the com-
plement activation profile seen in the guinea pig serum
samples exposed to MIC vapor in vitro (Table 2).
Namely, the CH50 values were reduced to a greater
extent than the C3 or C5 activity levels, and the C5
activity levels were reduced more than the C3 activity
levels.
Theproteinconcentrationofplasmasamplesobtained
from guinea pigs which had died from MIC exposure
(Table 3) were elevated significantly (p < 0.05) above
the pre-exposed protein concentrations as determined
by analysis of variance. In contrast, the protein con-
centrations ofplasma samples obtained fromthe paired
guinea pigs, which were sacrificed after MIC exposure,
werenotsignificantlydifferentfromthepredoseprotein
concentrations. Thus, as a result ofthese observed dif-
ferences in plasma protein concentrations, the func-
tional complement activity levels summarized in Tables
3 and 4 were normalized per milligram plasma protein.
These protein normalized values provide the best data
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Table 3. Complement parameters in guinea pigs found dead after exposure to 650 ppm MIC.
mg % Pre-exposed
MIC, Protein! C3H50 C5Ho/
Animal no. ppm CH54mL C3Hw/mL C5H)/mL mL CHs/mga mga mga CH50 C3H5W C5H5W
288 pre-exposed 1390 16900 9140 58 24.0 291 158
exposed 685 1170 17000 8330 67 17.5 254 124 72.9 87.3 78.4
293 pre-exposed 1750 18800 10900 56 31.3 336 195
exposed 644 1790 23100 11800 72 24.9 321 164 79.6 95.5 84.1
299 pre-exposed 1430 17400 9580 57 25.1 305 168
exposed 702 1310 21100 10300 68 19.3 310 151 76.9 101.6 89.9
301 pre-exposed 1490 16300 8890 57 26.1 286 156
exposed 691 1510 19700 10700 70 21.6 281 153 82.8 98.3 98.1
304 pre-exposed 1320 15600 9820 51 25.9 306 193
exposed 648 1080 17900 9640 65 16.6 275 148 64.1 89.9 76.7
Average ± SD
pre-exposed674 ± 26 1476 ± 165 17000 ± 1210 9666 ± 780 56 + 3 26.5 ± 2.8 305 ± 20 174 ± 19
exposed 674 26 1372 285 19760 ± 2451 10154 ± 1286 68* 3 20.0* ±3.4 288 ± 27 148* 1575.3* ±7.2 94.6 ± 5.8 85.5* ± 8.8
aThe per milligram protein normalization calculations were based on the Folin protein determination values using bovine serum albumin for
the standard curve.
*Significantly different from pre-exposed values, p <0.05.
Table 4. Complement parameters in guinea pigs sacrificed after exposure to 650 ppm MIC vapor.
mg % Pre-exposed
MIC, Protein/ C3H5I C5H54/
Animal no. ppm CH5J/mL C3H5/mL C5H50/mL mL CH5(mga mga mga CH50 C3H5W C5H50
302 pre-exposed 1410 17000 9940 54 26.1 315 184
exposed 685 864 14200 6900 50 17.3 284 138 66.3 90.2 75.0
296 pre-exposed 1360 15800 10000 57 23.9 277 175
exposed 644 609 13900 7270 70 8.7 199 104 36.4 71.8 59.4
303 pre-exposed 1390 19000 9640 56 24.8 339 172
exposed 702 745 16500 7690 54 13.8 306 142 55.6 90.3 82.6
298 pre-exposed 1730 19000 11800 53 32.6 358 223
exposed 691 700 14200 5800 53 13.2 268 109 40.5 74.9 48.9
305 pre-exposed 1560 18300 11200 55 28.4 333 204
exposed 648 1000 17200 9880 58 17.2 297 170 60.6 89.2 83.3
Average ± SD
pre-exposed 674 ± 26 1490 155 17820 1394 10516 933 55 ± 2 27.2 3.5 324 ± 31 192 22
exposed 674 ± 26 784 152 15200* 1531 7510* 1500 57 ± 8 14.0* 3.5 271 ± 43 133* 2751.9* ± 13 83.3 ± 9 69.8* ± 15
aThe per milligram protein normalization calculations based on the Folin protein determination values using bovine serum albumin for the
standard curve.
*Significantly different from pre-exposed values, p <0.05.
for comparative purposes since it appears that these
animals have lost water from their circulatory systems
with the retention of plasma proteins. This conclusion
is supported by the C3H5JmL data presented in Table
3. The average pre-exposure C3HrO values in these an-
imals was 17,000 units/mL. The average C3H50 values
in the same animals after death was 19,760 units/mL.
It is highly unlikely that the livers of these animals
synthesized sufficient quantities of C3 in 11-15 min to
increase functional C3 levels in their circulating plasma
by 16%. The C3 levels in the plasma obtained from the
sacrificed animals, which expenenced the same MIC
exposure, showed no corresponding increase. These ob-
servations suggest that guinea pigs that died upon MIC
exposure experienced shock, or possibly an anaphylac-
toid reaction before death resulting in the loss offluid,
but not plasma proteins, from their circulatory system.
This conclusion is at least partially supported by the
studies ofTroup et al. (26), whichreported asignificant
increase in plasma hematocrit levels observed in rats
exposed to 1000 ppm MIC for periods of1 hr or longer.
The MIC-induced activation of C5 in vivo, as evi-
denced by the results presented in Tables 3 and 4, may
be amajorcontributorto theincreased hematocrit (26),
neutrophilia (26), and pulmonary perivascular neutro-
phil extravasation (18) observed in MIC-treated ani-
mals. This would be the case whether C5 activation
occurredintheseanimals as aresultofsequential, phys-
iological complement pathway activation or as an iso-
lated event as exemplified by the activation of C5 by
noncomplement proteases. Thus, a variety of noncom-
plement enzymes, e.g., the neutrophil lysosomal pro-
teases elastase (27) or cathepsin G (28), as well as the
coagulation enzymes plasmin (29), and a-thrombin
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(29,30), can hydrolyze C5 to form either a modified C5'
molecule or C5 fragments that express C5a-like biolog-
ical activities (15,27-31). Either one or both C5 acti-
vation mechanisms) could be operational in MIC-
treated animals as a result ofthe rapid bronchiolar ep-
ithelial necrosis and sloughing, described by Fowler et
al. (18), leading to the influx ofplasma proteins into the
major airways. The exposure ofplasma complement to
necrotic cells would result in classical pathway activa-
tion (32,33) and C5a anaphylatoxin production. Alter-
natively, proteolyticenzymesreleasedfromthenecrotic
epithelium, infiltrating neutrophils, or blood clots could
lead to the activation of C5 directly (27-31).
Althoughtheseresultssuggestthatguineapigswhich
died subsequent to MIC vapor exposure experienced
either shock or an anaphylactoid reaction, which may
have contributed to the animals' death, the extent of
complement activation was actually greater in the
guinea pigs that did not die but were sacrificed. This
can be seen clearly by comparing the average percent
of pre-exposure CH50mg, C3H50mg, and C5H5Jmg
values for the sacrificed animals (Table 4) with these
same values obtained for the animals that died as a
result of MIC exposure (Table 3). Taken singularly,
these data suggest that intravascular complement ac-
tivation may help delay the onset of death in these an-
imals. Alternatively, the sacrificed animals may have
been less susceptible to the deleterious effects ofMIC-
induced complement activation.
In conclusion, the in vitro exposure of human or
guinea pig serum and matched EDTA-plasma samples
or the in vivo exposure of guinea pigs to MIC vapor
inducedprofound alterationsinthecomplement system.
These complement alterations resulted in reductions of
several key complement component functional activi-
ties. However, the complement activity profiles ob-
served inlimited invitro studies werevery unusual and
could not be explained fully on the basis of a normal,
physiological activation event. Therefore, a comple-
ment-independent mechanism must be invoked, e.g.,
direct MIC chemical inactivation of one or more com-
plement proteins, to explain the reductions in comple-
ment activity levels observed in the one human, and
one guinea pig MIC-exposed EDTA-plasma sample.
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